FMP

FMP

Enter

PACB - Pacific Biosciences ...

photo-url-https://images.financialmodelingprep.com/symbol/PACB.png

Pacific Biosciences of California, Inc.

PACB

NASDAQ

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

1.36 USD

-0.02 (-1.47%)

PACB Financial Statements

Year

2024

2023

2022

2021

Current Assets

495.68M

742.05M

855M

1.11B

Cash & Short Term Investments

389.93M

631.42M

772.32M

1.04B

Cash And Cash Equivalents

55.37M

179.91M

325.09M

460.73M

Short Term Investments

334.56M

451.5M

447.23M

583.67M

Net Receivables

27.52M

36.62M

18.79M

24.24M

Inventory

58.76M

56.68M

50.38M

24.6M

Other Current Assets

19.47M

17.34M

300k

500k

Non-Current Assets

764.77M

1B

912.09M

901.24M

Property, Plant & Equipment

46.6M

69.03M

81.34M

79.12M

Goodwill And Intangible Assets

707.33M

919.25M

820.22M

820.95M

Goodwill

317.76M

462.26M

409.97M

409.97M

Intangible Assets

389.57M

456.98M

410.25M

410.98M

Long Term Investments

0

12M

2.92M

4.59M

Tax Assets

0

1

-2.92M

-4.59M

Other Non-Current Assets

10.84M

3.7M

10.53M

1.17M

Other Assets

0

0

0

0

Total Assets

1.26B

1.75B

1.77B

2.01B

-

-

-

-

Current Liabilities

66.3M

95.03M

76.92M

83.29M

Accounts Payable

16.59M

15.06M

12.03M

11M

Short Term Debt

10.03M

490k

10.73M

1.61M

Tax Payables

0

0

0

0

Deferred Revenue

13.86M

16.34M

32.29M

36.03M

Other Current Liabilities

3.22M

7.84M

168.6M

4.15M

Total Current Liabilities

66.3M

95.03M

76.92M

83.29M

Total Non-Current Liabilities

687.55M

949.68M

1.13B

1.13B

Long-Term Debt

662.41M

892.24M

897.18M

898.37M

Deferred Revenue

0

5.53M

1.79M

25.05M

Deferred Taxes Liabilities

0

0

0

-25.05M

Other Non Current liabilities

25.15M

20.3M

800k

170.89M

Total Liabilities

753.85M

1.04B

1.2B

1.22B

Other Liabilities

0

0

0

0

Stockholders Equity

506.59M

701.3M

562.9M

790.99M

Common Stock

0

268k

227k

221k

Retained Earnings

-2.15B

-1.84B

-1.53B

-1.22B

Accumulated Other Comprehensive Income/Loss

422k

219k

-4.76M

-1.09M

Other Shareholders Equity

2.66B

0

0

0

Total Liabilities and Stockholders Equity

1.26B

1.75B

1.77B

2.01B

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

-1.84B

-1.53B

-1.22B

-1.04B

Net Income

-309.85M

-306.74M

-296.93M

-181.22M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-2.15B

-1.84B

-1.53B

-1.22B

Other Distributions

-309.85M

-306.74M

-314.25M

-181.22M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

46.6M

69.03M

81.34M

79.12M

Annual Depreciation

53.35M

26.53M

17.32M

11.59M

Capital Expenditure

-6.19M

-8.84M

-16.93M

-5.93M

Net PPE

-567k

51.33M

80.95M

73.47M

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

-144.5M

52.29M

0

409.97M

Goodwill (Previous Year)

462.26M

409.97M

409.97M

0

Goodwill

317.76M

462.26M

409.97M

409.97M

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep